

GOALS FOR 2007

LATE-STAGE PROGRAMS

CETRORELIX

- ▶ Initiate 2nd trial of Phase 3 program in BPH
- ▶ Initiate safety trial of Phase 3 program in BPH
- ▶ Announce full recruitment of first Phase 3 trial in BPH
- ▶ Disclose Japanese Phase 2 results in BPH

OZARELIX

- ▶ Disclose detailed European Phase 2 results in BPH
- ▶ Disclose top line U.S. Phase 2b results in BPH
- ▶ Disclose top line Phase 2b results in prostate cancer

PERIFOSINE

- ▶ Complete patient enrollment for Phase 2 trial in non-small cell lung cancer
- ▶ Disclose more Phase 1 and Phase 2 results in multiple cancers
- ▶ Initiate additional Phase 2 trials in multiple cancers


EARLIER-STAGE PROGRAMS

AN-152

- ▶ Disclose detailed Phase 1 results for breast and ovarian cancer
- ▶ Initiate Phase 2 program in ovarian and endometrial cancer

ZEN-012

- ▶ Initiate Phase 1 trial in solid tumors and lymphoma
- ▶ Announce top line results of Phase 1 trial in solid tumors and lymphoma



PRECLINICAL

- ▶ Disclose results for multiple programs
 - LHRH peptidomimetics
 - Erk/PI3K inhibitors
 - Erucyl-PC
 - Ghrelin antagonists
- ▶ Announce filing of an IND for a Phase 1 program